• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
New Procedure Saves Lives through Early Pancreatic Cancer Detection

New Procedure Saves Lives through Early Pancreatic Cancer Detection

by Zina | Dec 17, 2019 | Press Coverage

Courtesy of The Ohio State University Wexner Medical Center: Overall cancer survival has dramatically improved over the past two decades. However, the prognosis for pancreatic cancer remains bleak, with five-year survival at just 9 percent. Patients usually...
Mauna Kea Technologies Announces Strategic Equity Investment of €7.5 Million by Johnson & Johnson Innovation

Mauna Kea Technologies Announces Strategic Equity Investment of €7.5 Million by Johnson & Johnson Innovation

by Zina | Dec 16, 2019 | News

Mauna Kea Technologies today announced a strategic equity investment of 7.5 million euro by Johnson & Johnson Innovation – JJDC, Inc. (JJDC). Pursuant to the agreement, JJDC, the strategic venture capital arm of Johnson & Johnson, will subscribe to...
Mauna Kea Technologies Announces Strategic Equity Investment of €7.5 Million by Johnson & Johnson Innovation

Mauna Kea Technologies Participates in Dutch Molecular Imaging Consortium that was Awarded €5.4 Million

by Zina | Nov 7, 2019 | News

MEDPHOT consortium aims to develop light-based molecular imaging solution for pulmonary diseases  Mauna Kea Technologies today announced it is part of a molecular imaging consortium that was awarded €5.4 million by the Perspective Program of the...
Mauna Kea Technologies Announces Strategic Equity Investment of €7.5 Million by Johnson & Johnson Innovation

Third Quarter Sales and First Nine Months of 2019 Sales

by Zina | Oct 17, 2019 | News

READ THE COMPLETE PRESS RELEASE
Positive Results on  Needle-Based Endomicroscopy for Differentiating and  Managing Pancreatic Cystic Lesions

Positive Results on Needle-Based Endomicroscopy for Differentiating and Managing Pancreatic Cystic Lesions

by Zina | Oct 9, 2019 | News

Three recent clinical publications demonstrate that Cellvizio® AQ-Flex™ 19 Confocal Miniprobe significantly improves diagnostic accuracy versus standard of care, positively impacting management of patients with pancreatic cystic...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 
  • Publication of the 2024 Annual Financial Report 
  • Digestive Disease Week 2025
  • Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 
  • Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}